You're viewing our updated article page. If you need more time to adjust, you can return to the old layout.

CORRECTION article

Front. Chem., 18 June 2024

Sec. Medicinal and Pharmaceutical Chemistry

Volume 12 - 2024 | https://doi.org/10.3389/fchem.2024.1443822

Corrigendum: HSA-nanobinders crafted from bioresponsive prodrugs for combined cancer chemoimmunotherapy–an in vitro exploration

  • 1. Institute for Organic Synthesis and Photoreactivity (ISOF), National Research Council of Italy (CNR), Bologna, Italy

  • 2. Department of Science and High Technology, University of Insubria, Como, Italy

  • 3. Pharmacy Unit, Veneto Institute of Oncology IOV-IRCSS, Padua, Italy

  • 4. Department of Biology (DiBio), University of Padova, Padua, Italy

  • 5. Department of Pharmacy and Biotechnology (FaBiT), University of Bologna, Bologna, Italy

Article metrics

View details

1

Citations

882

Views

323

Downloads

In the published article, there was an error in the Affiliation. Matilde Tubertini’s second affiliation was missing. The correct affiliations appear above.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Statements

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

prodrugs, chemotherapy, IDO1 inhibition, endogenous human serum albumin, carrier-free nanoparticles, truncated evans blue, triple-negative breast cancer

Citation

Tubertini M, Menilli L, Milani C, Martini C, Navacchia ML, Nugnes M, Bartolini M, Naldi M, Tedesco D, Martella E, Guerrini A, Ferroni C, Moret F and Varchi G (2024) Corrigendum: HSA-nanobinders crafted from bioresponsive prodrugs for combined cancer chemoimmunotherapy–an in vitro exploration. Front. Chem. 12:1443822. doi: 10.3389/fchem.2024.1443822

Received

04 June 2024

Accepted

05 June 2024

Published

18 June 2024

Approved by

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Volume

12 - 2024

Updates

Copyright

*Correspondence: Greta Varchi, ; Francesca Moret,

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics